ArticlePediatric cardiology2018
Prognostic Value of Serum Apelin Level in Children with Heart Failure Secondary to Congenital Heart Disease.
Article in Pediatric cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Apelin and its ratio to lipid factors are associated with cardiovascular diseases: A systematic review and meta-analysis.PloS one · 2022Pooled it
- Apelin Levels in HFrEF and Association with Sustained VT Detected by ICD Interrogation: A Retrospective Pilot Study.Journal of cardiovascular development and disease · 2026Article
- Apelinergic System Affects Electrocardiographic Abnormalities Induced by Doxorubicin.Biomedicines · 2025Article
- Early Administration of Apelin Could Prevent Heart Failure Following Myocardial Injury; A Systematic Review and Meta-Analysis.Archives of academic emergency medicine · 2025Review
- Decreased plasma ELABELA level as a novel screening indicator for heart failure: a cohort and observational study.Scientific reports · 2024Observational
- Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024Review
- The Elabela-APJ axis: a promising therapeutic target for heart failure.Heart failure reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apelin is an endogenous inotrope that decreased in heart failure (HF). We aimed to evaluate the prognostic value of its level in children with HF due to congenital heart disease (CHD). Sixty children with HF due to CHD were included as a patient group. Sixty healthy children matched for age, sex, and weight served as a control group. Chest X-ray, electrocardiogram (ECG), echocardiography, and laboratory investigations such as complete blood count, c-reactive protein, and serum apelin levels were performed for all included children at admission. All children were followed up for 3 months. Serum apelin level was significantly decreased in patients with HF at admission than healthy control group and this decrease went with advanced stage of HF. Serum apelin levels were significantly decreased in patients with unfavorable prognosis than those with favorable prognosis. At a cutoff lower than 126 ng/l, the sensitivity of serum apelin to predict unfavorable prognosis in children with HF was 96% with a specificity of 82%. Serum apelin level had a significant positive correlation with left ventricular systolic function (P < 0.05). Moreover, it had a significant negative correlation with heart rate, respiratory rate, Ross classification, c-reactive protein, cardiothoracic ratio, and both left and right ventricular dimensions (P < 0.05). Serum apelin level has a good predictive value for adverse outcome in children with HF due to CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.